ProjectV–Arandomizedcontrolledprospectivestudyofthenext-generationprobiotic,V e i l l o n e l l aa t y p i c aFB0054,vsplaceboinhealthyadults
Version
Date:May16,2023
Protocol
Version: 
Protocol
Number:
01
FB004
Sponsor:
FitBiomics,
Inc. 
[ADDRESS_548777] 
6
th
Floor 
New
York,
NY
[ZIP_CODE]
Principal
Investigator:
[INVESTIGATOR_433072],
Inc 
[ADDRESS_548778] 
6
th
Floor 
[EMAIL_8274]
Participating
Sites:
FitBiomics,
Single
Site
Study

TableofContentsTableofContents2
TableofAcronyms4
Title4
PrincipalInvestigator4
StudySynopsis4
BackgroundandRationale4
Objectives5
StudySupplement5
SubjectSelection5
InclusionCriteria5
ExclusionCriteria5
Researchequity6
VulnerablePopulations6
StudyProcedures6
Recruitment6
DetailsStudyProcedures6
Figure1.StudyProcedures7
Table1.SurveyDetails7
Table2.SurveySchedule8
CompletingResearchActivities8
Compensation8
Researchresultsorclinicalfindingsarisingfromresearchactivities8
Risk/SafetyInformation9
ForVeillonella:9
ForPlacebo:9
Otherrisksofstudyprocedures9
UnforeseenRisks9
RiskLevelDetermination9
AlternativestoParticipation9
ParticipantWithdrawalfromResearch/ResearchActivities9
Monitoring/ReportingofAE/SAE10
StudyOversight10
1
EthicalandRegulatoryStandard10
IRBReview/Ethics/InformedConsent11
StudyComplianceandReportingDeviations11
ConditionsforStudyTerminationorSuspension12
InformedConsent12
PrivacyAuthorization12
Stateof[LOCATION_004]HumanExperimentationRequirements13
DataManagement13
Confidentiality13
ReturnorClinicalUseofResearchResults13
IntendedUseoftheData14
Information/DataRetention,FutureUse,andSharing14
Publication14
BiostatisticalAnalysisPlan14
DataSource14
AnalysisObjectives14
AnalysisSets/Populations/Subgroups14
Endpoints15
HandlingofMissingValues15
StatisticalProcedures15
MeasurestoAdjustforConfounders16
QCPlans16
ProgrammingPlans16
InvestigatorConflictofInterest16
References17
2
TableofAcronyms
(inalphabeticalorder)
AcronymDefinition
AEAdverseEvent
BMIBodyMassIndex
CFRCodeofFederalRegulations
ChloeConsumerHealthLearningandOrganizingEcosystem
FDAFoodandDrugAdministration
GCPGoodClinicalPractice
GSEGeneralSelfEfficacy(aquestionnaire)
HIPAAHealthInsurancePortabilityandAccountabilityAct
ICHInternationalCouncilforHarmonization
IRBInstitutionalReviewBoard
I/EInclusion/Exclusion(criteria)
MFIMulti-dimensionalFatigueInventory(aquestionnaire)
NIHNationalInstituteofHealth
PI[INVESTIGATOR_433073]
3
StudySynopsis
Inthisstudy,weareassessingtheabilityofVeillonella(Veillonellaatypi[INVESTIGATOR_433074]0054)todecreasefatigueandincreaseenergyinaheterogeneouscohortofhealthyadultscomparedtoplacebo.Studysubjectswillfilloutabaselinehealthandhabitsurveyfollowedby[CONTACT_433081],fatigue,andenergylevels.Afterthis,subjectswilltakeonedailycapsuleorallyofoneoftwodosesofVeillonellaorplaceboforfourweeks,whileagainfillingoutbothdailyandweeklysurveys.Finally,therewillbeatwoweekwashoutperiodwithnosupplementationbutonlydailyandweeklysurveys.Attheendofthestudy,therewillbeafinalexperiencesurvey.
BackgroundandRationale
Veillonellaisanovelprobioticthatcanmetabolizelacticacidintopropi[INVESTIGATOR_16847],whichisanenergysourceforthebody[1,2].Inpreviousresearch,wehaveshownthatVeillonellacanimproveendurancecomparedtoplacebo.Inmousestudies,thosemicewhosupplementedwithV.atypi[INVESTIGATOR_433075]13%longerinarun-to-exhaustiontestthanthosemicewhoweregivenplacebo[1].Furthermore,inarandomizedcontrolledcrossoverpi[INVESTIGATOR_290988],wecouldshowthatVeillonellaprevented78.7%oftheperformancedeclineobservedintheplacebogroupi[INVESTIGATOR_433076]-to-exhaustionmodel[3].WehavealsoconductedexperimentsthathaveresultedinthisproductbeingdeemedGenerallyRegardedAsSafe(GRAS)[4].
Therefore,webelievetheVeillonellaissafeandlikelytoprovidesignificantbenefitsintermsofimprovedendurance,increasedenergy,anddecreasedfatigue.Thisresearchstudyisdesignedtotestthathypothesis.FitBiomicsissponsoringthisstudytoconfirmtheseeffectsinabroaderpopulation.FitBiomicsisthefirstcompanytodevelopthistypeofbacteriaasaprobiotic,andthiswillbethelargeststudytestingthesafetyandefficacyofthisprobiotic.
Objectives
Thepurposeofthisresearchstudyisto:
●Testthesafetyandeffectivenessofthestudydrug,Veillonella(Veillonellaatypi[INVESTIGATOR_433074]0054),anext-generationprobioticstrain.
●Identifythetypesofbenefitsobservedinabroadpopulation
StudySupplement
ThestudysupplementhereincludesoneoftwodosesofVeillonellaorplacebo.VeillonellacontainsVeillonellaatypi[INVESTIGATOR_433074]0054astheactiveingredientwithmicrocrystallinecelluloseandhypromelloseasexcipi[INVESTIGATOR_840].Thetwodosesare15billioncfu(highdose)and7.5billioncfu(lowdose).Placebocapsulescontainmicrocrystallinecelluloseandhypromellose.BothVeillonellaandplaceboareencapsulatedinacid-resistantcapsulestoimprovedeliverytothelargeintestine,whichparticipantswilltakeorallyathomeonadailybasisforfourweeks.
4
SubjectSelection
ParticipantsinthisstudywillbehealthyadultsinterestedinusingVeillonellatoreducefatigueandincreaseenergy.Subjectswillbeexcludedfromthestudyiftheyhaveconditions,diseases,ormedicationsthatcouldresultinincreasedlikelihoodofAEsrelatedtoVeillonellause.
InclusionCriteria
●Maleorfemaleadultsaged18–65years.
●Willingandabletoprovidewritteninformedconsent.
●Abilityoftheparticipanttocomprehendthefullnatureandpurposeofthestudyincludingpossiblerisksandsideeffects.
●Agreementtocomplywiththeprotocolandstudyrestrictions.
●FluentinwrittenandspokenEnglish.
●Ingoodgeneralhealthasjudgedby[CONTACT_433082].
●Willingtomaintaindailyexerciseanddiethabitsthroughoutthe8weekstudywithoutmakingmajorlifestylechanges.
●AbilitytouseapersonalsmartphonedeviceanddownloadtheChloeappby[CONTACT_433083]
●Currentlypregnant,planningtobecomepregnant,orlactatingduringthenext12weeks
●Haveasignificantacuteorchroniccoexistingillness,disorder,orconditionthatcontraindicates,inthePrincipalInvestigator'sjudgment,entrytothestudy.
●Currentlytakingimmunosuppressivemedications.
●Isconsideredimmunosuppressedforanyreason.
●Currentlytakingmedicationsthatcouldimpairtheintegrityofthegutepi[INVESTIGATOR_24603]
●Hassymptomsoranillness,disorder,orcognitionthatimpairstheintegrityofthegutepi[INVESTIGATOR_24603].
●Currentantibioticuseorplannedoralantibioticuseoverthecourseofthestudy.
●Investigatorbelievesthattheparticipantmaybeuncooperativeand/ornoncompliantandshouldthereforenotparticipateinthestudy.
ResearchequityThisresearchhasnodirectexclusionsrelatedtogender.Therearealsonodirectexclusionsrelatedtoraceorethnicity.
VulnerablePopulationsVulnerablepopulationsarenotspecificallytargetedinthisresearch.Racialandethnicminoritieswillbeincludedintheparticipantsbutarenotspecificallytargetedforinclusion.
StudyProcedures
SeeFigure1fordetailsofstudyprocedures.
Recruitmen tParticipantswillberecruitedtothestudyviaemailandsocialmedia.Interestedparticipantswillsignupthoughtheonlinestudylandingpage.Participantswillbechosenfromthepoolofsignupsbasedonthe
5
inclusionandexclusioncriteriaabove.Thereisnomaximumnumberofparticipants.Allthoseeligiblewillbeinvitedtoparticipate.However,weestimateupto1,000participantswillbeinvitedtoparticipateinthestudy.
DetailsStudyProceduresOnceparticipantsareinvitedtothestudy,theywillbesentanemailwithalinktotheChloeapplication,whichtheywilldownloadtotheirmobiledevice.Chloewillleadthemthroughadetaileddescriptionofthestudyandtheinformedconsentprocess.Atthispoint,theywillalsoconsenttosharingtheirfitnesstrackerdata,asanoption,iftheyhaveone.Thefitnesstrackerdatawillbeusedtoanswersleepquestionsandotherfitnesstrackerdatawillbestoredforanalysisby[CONTACT_433084].Onceinformedconsentisobtained,participantswillfilloutabaselinehealthandlifestylesurvey,wheretheywillalsosharetheirmailingaddress.Oncethissurveyiscompleted,theparticipantwillberandomizedtoahighdoseVeillonella(15billioncfu),lowdoseVeillonella(7.5billioncfu),orplaceboina4:4:2ratiorespectively.Thesecapsuleswillbemailedtotheparticipantduringthe2weekbaselineperiod.
Completionoftheinitialbaselinehealthandhabitsurveyinitiatesthe2weekbaselineperiod.Duringthisperiod,participantswillfilloutdailysurveysonsleep,energy,andbowelmovementsandweeklysurveysonotherbenefitsandadverseevents(AEs)theyhavenoticed(moredetailsonallsurveyscanbefoundinTables1and2).Onthefinaldayofthetwoweekbaseline,theywillalsofillouttheMultidimensionalFatigueInventory(MFI)andGeneralSelf-Efficacy(GSE)questionnaires.Atthispoint,participantswillbeginsupplementation.Participantswillsupplementwithonecapsuledailyfor4weeks.Duringthesupplementationphase,participantswillfilloutthesamedailyandweeklysurveys.Onthefinaldayofthesupplementationperiod,participantswillalsofillouttheMultidimensionalFatigueInventoryandGeneralSelf-Efficacyquestionnaires.Aftersupplementation,therewillbeatwoweekwashoutperiodtomonitorpatientsandtounderstandthelastingeffectofanybenefitstheyexperienced.Duringthewashoutperiod,participantswillagainfilloutthesamedailyandweeklysurveys.Onthefinaldayofthewashoutperiod,therewillbetwoadditionalsurveys:onewithsomeadditionalquestionsonchangesobservedthroughoutthestudyandoneofopenendedquestionsonthewholestudyexperience.
6
Figure1.StudyProcedures
Table1.SurveyDetails
SurveyNameSurveyDetailsNumberofQuestionsEstimatedTimetocompleteNumberofTimesUsedTotalsurveytime
StudysignupformFormusedtoexpressinterestinthestudy,includesquestionsonparticipan tdemographicsandtoinclude/excludeparticipan ts185minutes1X5minutes
BaselinesurveyIncludesquestionsondailyhabitsandlifestyleaswellasbaselinequestionsonnormalfatigueandenergylevels3110minutes1X10minutes
DailysurveyDailyassessmen toftheparticipan t’ssleep,energy,andbowelmovements4<1minute56X56minutes
WeeklySurveyParticipan tsareaskedtolookbackattheirweekandreporttheirfeelingsoffatigue,energy,mood,andhealth,aswellastheirexerciseandotherphysicalactivity185minutes8X40minutes
7

MFIAself-reportinstrumentdesignedtomeasurefatigue.Itcoversthefollowingdimensions:GeneralFatigue,PhysicalFatigue,MentalFatigue,ReducedMotivationandReducedActivity.205minutes2X10minutes
GSEPROMISself-efficacysurveydesignedtobenon-diseasespecificmeasureoflifemanagementandphysicalfunctioning4<1minute22minutes
EndofstudysurveyArepetitionofsomequestionsfromthebaselinesurveytoassesswhethertherehavebeensignificantchangesoverthecourseofthestudy4<1minute11minute
ExperiencesurveyMostlyopenendedquestionsonexperienceinthestudyitself,includingquestionsdesignedtoinformfuturemarketingofVeillonella65minutes15minutes
Totalsurveytime139minutes
Table2.SurveySchedule
RecruitmentPre-Week1Week1Week2Week3Week4Week5Week6Week7Week8
Studysignupform1X
Informedconsent1X
Baselinesurvey1X
DailysurveyDaily(7X)Daily(7X)Daily(7X)Daily(7X)Daily(7X)Daily(7X)Daily(7X)Daily(7X)
Weeklysurvey1Xatendofweek1Xatendofweek1Xatendofweek1Xatendofweek1Xatendofweek1Xatendofweek1Xatendofweek1Xatendofweek
MFI1Xatendofweek1Xatendofweek
GSE1Xatendofweek1Xatendofweek
Endofstudysurvey1Xatendofweek
8
Experiencesurvey1Xatendofweek
CompletingResearchActivities
Compensa tionParticipantswillreceivepointsintheChloemobileapptobeusedtowardanAmazonGiftCardandbeprovidedwithadiscountcodetopurchasetheNellaprobiotic.
ResearchresultsorclinicalfindingsarisingfromresearchactivitiesDuetothenatureofthestudy,itisunlikelythatresearchresultsorfindingsfromresearchactivitieswillresultinfurthermedical-relatedexpensesfortheparticipant.
Risk/SafetyInformation
Startinganewprobiotictendstoresultinmildandtransientgastrointestinalupset.Inourpreviouspi[INVESTIGATOR_433077],wehaveobservedthesesymptoms,buttheyweremildenoughtonotinterferewitharun-to-exhaustionendpoint.Thesurveysusedinthisstudyincludeaquestiononpotentialsymptomsexperienced,whichwillallowustoidentifyadditionalpotentialAEsaswellasknownsideeffectsthatpersistlongerthanexpected.
ForVeillonella:Verycommon(greaterthanorequalto1/10)
●Mildgastrointestinalupsetincludingtemporaryincreasesingas,bloating,crampi[INVESTIGATOR_007],andnausea
●Nervousnessandincreasedfeelingsofanxiety
ForPlacebo:
●Noneknown
OtherrisksofstudyproceduresQuestionnaires:Thequestionsusedinthissurveymaycausetemporarydiscomfortordistresstotheparticipant.Thesurveyisdesignedtobesimpleandshortandisacommonlyusedtoolinclinicalstudies.Theparticipantmaychoosenottocompletethequestionnaire.
BreachofConfidentiality:Thereisminimalriskthatpeoplewhoarenotconnectedwiththisstudywilllearnoftheparticipant’sidentityorpersonalinformation.ThestudystaffwillbeGCPtrainedandwillutilizebestpracticeswhenusingthedataplatformtoensureparticipantprivacyprotections.
UnforeseenRisksTheremaybeotherrisksthatareunknown.Additionally,theremaybeunknownriskstoapregnancy,embryo,orfetusifyouoryourfemalepartnerbecomepregnant.
9
RiskLevelDeterminationTheriskstothestudyareminimalorunanticipatedduetoappropriatemitigationmeasures(e.g.breachofconfidentiality,lossofinternetaccess).Thisresearchmeetsthefederallydefineddefinitionofminimalrisk(45CFR46.102(j)).
AlternativestoParticipationTheindividualcanchoosenottoparticipate.
Participan tWithdrawalfromResearch/ResearchActivitiesResearchactivitiesarelimitedtofiveweeks.
Participantsmaywithdrawfromthestudyatanytimeandforanyreasonwithoutprejudice.Thewithdrawalmustbedocumented.
Monitoring/ReportingofAE/SAE
AEsandSAEswillbedetectedusingtheweeklysurveys.Onaweeklybasis,participantsareaskediftheyhavestoppedtakingtheproductduetosideeffects.Iftheyanswerintheaffirmative,theycanprovidemoreinformationonthesymptomsandtheirseverity.ParticipantscanalsoreportAEsandSAEstothestudystaffatanytimeviaphoneoremail.
AnAEisdefinedasanyreportedsideeffectoftheproductthatislikelyduetoVeillonellaitself.Basedonourpreviouswork,weanticipatemildandtransientgastrointestinalupsetaswellasmildanxietyaspossiblecommonAEs.
AnSAEisdefinedasanysevereand/orunexpectedsideeffectthatislifethreatening,requiresmedicalorsurgicalintervention,orisotherwiseanimportantmedicaleventforthepatient.SAEsarealsoAEsthatresultinhospi[INVESTIGATOR_059],disabilityorpermanentdamage,ordeath.ThesewillbereportedtotheFDA.
FitBiomicsisutilizingacompanycalledSafetyCallforAEmonitoringandreportinginthisstudy.SafetyCallwillprovideadverseeventmanagement,incidentdocumentation,andfirstaidadviceforbasicon-sitepatientmanagement,generalmedicalandclinicaltoxicologyconsultationforhealthcareproviders,andhealthandsafetyinformationtothestudyparticipants,customers,medicalpersonnel,andothers.Servicesareprovidedby[CONTACT_756]24hoursaday,365daysayear.
SafetyCallwillalsoprovideadverseeventmanagementandincidentdocumentationfornon-telephonebasedcorrespondencesuchasconsumeremail,customerservicenotifications,internet-basedinquiriesandwrittencommunications.Theseservicesincludeaninitialprofessionalassessmentforhealthriskandtriage.SafetyCallwillrespondtoanyinquiriesitreceives,includingincidentsinvolvingeitherhumansoranimalsconsistentwithstandardofcarepractices.Aleadtoxicologistisavailablefrom9:00amto5:00pmCentralStandardTime,MondaythroughFriday.Anon-calltoxicologistisavailableafterhours.
SafetyCallwillalsomanagereportingofAEstotheFDA.IncompliancewiththeDietarySupplementandNonprescriptionDrugConsumerProtectionAct(Pub.L.109-462,120Stat.3469),anycorrespondenceorverbalnotificationofapotentialadverseevent(AE)inassociationwithadietarysupplementreceivedby[CONTACT_433085]/oritssubsidiarieswillbedocumentedaccordingtoFDAmandateddatacollectionguidelinesandallrecordsretainedforaminimumof6yearsforpotentialreviewby[CONTACT_232028].Those
10
adverseeventsmeetingtheFDAdefinedcriteriaforseriouswillbereportedtotheFDAwithin15-businessdaysusingtheFDAForm3500Aanditsaccompanyingdataelements.
StudyOversight
Thisstudywillbemadeavailableformonitoring,auditing,IRBreviewandregulatoryinspectionby[CONTACT_433086].
EthicalandRegulatoryStandardThisstudywillbeconductedinconformancewiththeprinciplessetforthinTheBelmontReport:EthicalPrinciplesandGuidelinesfortheProtectionofHumanSubjectsofResearch(USNationalCommissionfortheProtectionofHumanSubjectsofBiomedicalandBehavioralResearch,April18,1979)andtheDeclarationofHelsinki.
ThisstudyistobeconductedincompliancewiththeIRBapprovedprotocolandaccordingtoapplicablefederal,state,localandtriballawsincludingthefollowing:
●USCodeofFederalRegulations(CFR)governingclinicalstudyconduct:Title45Part46–ProtectionofHumanSubjects
●USCodeofFederalRegulationsrelatingtotheHealthInsurancePortabilityandAccountabilityActof1996:Title45Part164–SecurityandPrivacy–SubpartE-
○SubpartE—PrivacyofIndividuallyIdentifiableHealthInformation
●Stateof[LOCATION_004]HealthandSafetyCode,Title17,forresearchconductedin[LOCATION_004]
Inaddition,thisstudyistobeconductedincompliancewithapplicablepoliciesandproceduresoftheAdvarraIRB,applicableinstitutionalresearchpoliciesandprocedures,applicableinstitutionalclinicalpoliciesandprocedures,andapplicableNIHpoliciesandprocedures.
IRBReview/Ethics/InformedConsentTheprotocol,informedconsentform(s),recruitmentmaterialsandallparticipantmaterialswillbesubmittedtotheAdvarraIRBforreviewandapproval.Approvalofboththeprotocolandtheconsentformmustbeobtainedbeforeanyparticipantisenrolled.Anyamendmentstotheprotocolorconsentmaterialswillrequirereviewandapprovalby[CONTACT_433087].
Perthefederalregulationsat45CFR46andStateof[LOCATION_004]HealthandSafetycode,Title17,mustreviewandapprovethisprotocolandtheinformedconsentprocessanditsdocumentspriortoinitiationofthestudy.Allinstitutional,NIH,Federal,andStateof[LOCATION_004]regulationsmustbefulfilled.
AnydocumentsthattheIRBmayneedtofulfillitsresponsibilities(suchasprotocol,protocolamendments,consentforms,informationconcerningparticipantrecruitment,paymentorcompensationprocedures,orotherpertinentinformation)willbesubmittedtotheIRB.TheIRB’swrittenapprovalofthestudyprotocolandtheinformedconsentdocumentwillbeinthepossessionoftheinvestigatorbeforethestudyisinitiated.
Anyamendmenttotheprotocoldocumentandaccompanyinginformedconsentdocuments,asdevelopedandprovidedby[CONTACT_32709],willrequirereviewandapprovalby[CONTACT_433088].
11
StudyComplianceandReportingDeviationsAdeviationisadivergencefromaspecificelementofaprotocolandthatoccurredwithoutpriorIRBapproval.Deviationsfromtheapprovedprotocolwillbeavoided,exceptwhennecessarytoeliminateanimmediatehazardtoaresearchparticipant.AlldeviationsfromtheprotocolwillbedocumentedinstudysourcedocumentsandpromptlyreportedtotheIRB.
Investigatorsmaydeviatefromtheprotocoltoeliminateimmediatehazardsfortheprotection,safety,andwell-beingofthestudysubjectswithoutpriorIRBapproval.Foranysuchdeviation,thePI[INVESTIGATOR_433078],within5calendardaysofitsoccurrenceby[CONTACT_433089].
ConditionsforStudyTerminationorSuspensionThisstudywillbeterminatedprematurelyinthefollowingsituations:
●Thereareunforeseensafetyissuesorifotherstudiesarepublishedthatindicateapresenceofunanticipatedtoxicityrisksthatcannotbeadequatelyquantified.
●Theprotocolisdeterminedtonolongermeetstudyorsponsorobjectives.
ThestudyPI[INVESTIGATOR_433079].Ifthestudyisprematurelyterminatedorsuspended,participantswillbeinstructedastowhethertheyshouldcompletesupplementation.Participantswillbemonitoredandcontinuefollowupfor2weeksaftertheystopsupplementationtoensuretheirsafetyandtocollectanyfinaldata.Allparticipantswhohavecompletedatleast50%ofsurveysatthetimethatthestudyisterminatedorsuspendedwillbeprovidedwithadiscountcodetopurchasetheNellaprobioticascompensation.
InformedConsentInformedconsentisaprocessthatisinitiatedpriortotheindividualagreeingtoparticipateinthestudyandcontinuesthroughoutstudyparticipation.Operationaldetailsspecifictotheconsentingprocessthatoccurspriortoanyresearchevaluations/interventionsaredescribedinSection6.0.
Allparticipantswillundergovirtualelectronicinformedconsentaftertheyaredeterminedtoqualifyforthestudy.Anelectronicinformedconsentdocumentwilldescribethenature,duration,purposeofthestudy,potentialrisks,alternativesandpotentialbenefits,andallotherIRBapprovedinformation.Inaddition,theexperimentalparticipant’sbillofrightsandtheHIPAAresearchauthorizationformwillbeprovided.Prospectiveresearchparticipantswillbeinformedthattheymaywithdrawfromthestudyatanytimeandforanyreasonwithoutprejudice.Prospectiveresearchparticipantswillbeaffordedsufficienttimetoconsiderwhethertoparticipateintheresearch.
Virtualinformedconsentwillbeconductedthroughtheapp-basedconsentformattheparticipant’sconvenience.Afterreadingtheconsent,participantswillbeabletocontact[CONTACT_433090].Oncetheprospectiveparticipantexpressesfullunderstanding,virtualinformedconsentwillbeobtainedthroughelectronicsignaturefromeithertheprospectiveparticipantbeforestudyparticipation.ThemethodofobtaininganddocumentingtheinformedconsentandthecontentsoftheconsentmustcomplywiththeICH-GCPandallapplicableregulatoryrequirements.AcopyofthesignedconsentdocumentwillbeavailabletotheparticipantwithintheChloeapp.Thesignedconsentmustbemaintainedby[CONTACT_433091],orregulatoryauthorityatanytime.
12
PrivacyAuthoriz ationTheinformedconsentprocesswillincludeaprivacyauthorizationcompliantwith45CFR164.508(c)viatheinclusion/incorporationof:
-allcoreelementsspecifiedin508(c)(1)includingthesignatureoftheindividual(orrepresentative)anddateofsignature,-allrequiredstatementsspecifiedin508(c)(2)-theplainlanguagerequirementasspecifiedin508(c)(3),and-theprovisiontotheparticipant(orrepresentative)acopyofthesignedauthorization(508(c)(4)
Stateof[LOCATION_004]HumanExperimen tationRequirementsThisresearchinvolvesthecollectionofinformationviavalidatedquestionnairesandobtaininginformationfromthemedicalrecord.Researchactivitiesdonotencompassthosethatarerequisiteforaparticipanttobeinvolvedina“medicalexperiment”asdefinedby[CONTACT_433092]24174.The‘[LOCATION_004]ExperimentalSubject’sBillofRights’willbeadministeredaspartoftheinformedconsentprocess;aspartofthatprocessparticipantswillreceiveacopyofthe‘BillofRights’markedwiththeirsignature.
DataManagement
Studydatawillbestoredinsecurepassword-protectedservers.Studystaffwillde-identifyalldatapriortodataanalysis.DatawillbeanalyzedtocomparethesafetyandefficacyofVeillonellavsplaceboandbetweenthetwodifferentdosesofVeillonella.Wewillalsousethesedatatobetterunderstandthetypeofbenefitsdifferentsubsetsofparticipantstendtoexperienceaswellasthemagnitudeofthebenefitinthesesubpopulations.Theseresultswillbeusedtocreatepeer-reviewedpublications,academicandindustrypresentations,filepatents,andpotentiallydevelopnewinnovativemicrobiomeproductslikeprobiotics.Participantswillnotbenotifiedofanyoftheseuses.
Confidentiality
Alldocumentsandelectronicdatawillbestoredonsecure,password-protectedcomputers.Participantconfidentialitywillbestrictlyheldintrustby[CONTACT_232033],studypersonnel,andsponsor.Noidentifierswillbeusedinanysubsequentpublicationoftheseresults.
Recordsofparticipationinthisstudywillbeheldconfidentialexceptwhensharingtheinformationisrequiredby[CONTACT_433093].TheInvestigator,thesponsororpersonsworkingonbehalfofthesponsor,andundercertaincircumstances,theUSFDAandtheIRBwillbeabletoinspectandcopyconfidentialstudy-relatedrecordsandidentifysubjectsby[CONTACT_2300].Thismeansthatabsoluteconfidentialitycannotbeguaranteed.Thisdoesnotlimitthedutyoftheresearchersandotherstoprotectparticipants’privacy.Studyrecordsincludingconfidentialinformationaboutstudysubjectscollectedduringthestudywillbekeptatasecurelocationorserver.Iftheresultsofthisstudyarepublishedorpresentedatmeetings,participantswillnotbeidentified.
13
Adescriptionofthisclinicaltrialwillbeavailableonhttp://www.ClinicalTrials.gov,asrequiredbyU.S.Law.ThisWebsitewillnotincludeinformationthatcanidentifyparticipants.Atmost,theWebsitewillincludeasummaryoftheresults.
ReturnorClinicalUseofResearchResultsParticipantswillbeshowntheirstudydatainrealtimeastheygothroughthedatavisualizationmodulesintheChloeplatform.
Researchresultswillbesharedwithparticipantsatcompletionofdataanalysis.Theresultsofthisresearchmayhelptheparticipantmakedecisionsinfutureproductpurchasesandparticipateinfutureresearchstudies.
Therearenoanticipatedburdensorfinancialobligationstoresearchsubjects.
IntendedUseoftheData
Information/Da taRetention,FutureUse,andSharingThedatacollectedaspartofthisstudywillbeusedtoassessthesafetyandefficacyofVeillonellainthispopulation.Thesedatamaybeusedinpeer-reviewedmanuscripts,researchpresentations,andothermaterialstopromoteFitBiomicsanditsplatform,ortodevelopnewproducts.Alldatawillbedeidentifiedpriortoanypublicationorpresentation.Priortothecompletionofthisresearch,informationwillbecoded,destroyed,de-identified,orprovidedtoaprivacyofficer.
PublicationThepublicationorpresentationofanystudyresultsshallcomplywithallapplicableprivacylaws,including,butnotlimitedto,theHealthInsurancePortabilityandAccountabilityActof1996.Neitherthecompletenoranypartoftheresultsofthestudycarriedoutunderthisprotocol,noranyoftheinformationprovidedby[CONTACT_433094],willbepublishedorpassedontoanythirdpartywithoutthewrittenapprovaloftheStudyPI.Anyinvestigatorinvolvedwiththisstudyisobligatedtoprovidethesponsorwithalldataderivedfromthestudy.
BiostatisticalAnalysisPlan
DataSourceThesourceofthedataistheresultsofthequestionnairesfilledoutthroughtheChloeappaswellastheoptionalfitnesstrackerdatacollectedoverthecourseofthestudy.
AnalysisObjectiv esThegoalsofthisanalysisaretoidentifywhethertherearestatisticallysignificantdifferencesineffectsbetweentheplaceboandVeillonellagroupsaswellasbetweenthehighandlowdoseVeillonellagroups.Furthermore,foranydifferencesthatareobserved,wewouldliketounderstandwhetherthereareanydemographicorotherparticipantcharacteristicsthatmaybeassociatedwithbenefitsorsideeffectsexperiencedby[CONTACT_433095].
14
AnalysisSets/Populations/SubgroupsThethreegroupscomparedinthisstudyarehighdoseVeillonella,lowdoseVeillonella,andplacebo.
Inaddition,weplantoseparatelyanalyzeresultsby[CONTACT_547],age,baselineexercisehabits,healthhistory,previousprobioticexperience,sleephabits,andotherlifestylefactors.
Forthoseparticipantswhosharefitnesstrackerdata,thefitnesstrackerdatasharedthroughtheChloeappwillbeanalyzedinconjunctionwithsurveydataseparatelyfromthosewhodidnotsharefitnesstrackerdata.
Endpoin tsTheprimaryendpointsanalyzedinthisstudyare:
-Changeinreportedphysicalfatigue-Changeinmental/emotionalfatigue-ChangeinMFI
Thesecondaryendpointsanalyzedinthisstudyare:
-Changeinreportedsleepquality-Changeinfrequencyofreportedphysicalactivity-Changeinintensityofreportedphysicalactivity-Changeinreportedexercise-Changeinrecoverytime-Changeinenergylevel
Theexploratoryendpointsanalyzedinthisstudyare:
-Changesinfitnesstrackerdata-Changeinreportedbowelmovements-ChangeinGSE-Changeinreportedmood-Changeinreporteddigestivehealth-Changeinreportedgeneralhealth-ChangeinBMI,weight,orwaistcircumference
HandlingofMissingValuesTherewilllikelybemissingvaluesrelatedtoincompleteormissingsurveys.Participantswillonlybeincludedintheanalysisiftheycompletedatleast50%ofweeklysurveysduringeachtimeperiod:baseline,supplementation,andwashout.Valueswillbebinnedlongitudinallysuchthateachparticipantincludedintheanalysishasadatapointassociatedwitheachbin.Iftherearemultiplevaluesassociatedwithaparticipantinabin,themeanofthosevalueswillbeusedfortheanalysis.
StatisticalProceduresThemajorityofprimaryandsecondaryendpointsforthisstudyarequestionsonthesurveywhichconsistofratingscales(generally1-5or1-9).SignificantdifferencesbetweengroupsfortheseendpointswillbeassessedusinganindependentTtestorMann-WhitneyUtestdependingontheobserved
15
distributionofthedata.Forsignificantchangesovertimewithinthesamegroup,adependentTtestwillbeused.
Fordifferencesbetweengroupsintermsofprimaryandsecondaryendpointsthatmeasureachangeintime(e.g.timetorecoveryindaysorhoursofsleep),anindependentTtestorMann-WhitneyUtestwillbeused,dependingontheobserveddistributionofthedata.Forsignificantchangesovertimewithinthesamegroup,adependentTtestwillbeused.
Toidentifydemographicsassociatedwithanyparticularresponse(benefitorsideeffects),wewillusethedemographic,healthhistory,andlifestyleinformationcollectedinthesurveystobuildanunsupervisedmachinelearningalgorithm(e.g.RandomForestClassifier).Ifwecanbuildonethateffectivelyclassifiestheresponse(AUC>0.7),wewillidentifythemodel’smostimportantfeatures.Toconfirmthatthesefeaturesaresignificantlyassociatedwithresponse,wewilluseanindependentTtesttoassesssignificantdifferencesbetweenresponseandnon-response.
Forallotherexploratoryendpointsincludingtheoptionalfitnesstrackerdata,thedatatypeanddistributionofthatdatawilldeterminethestatisticalanalysisused.
MeasurestoAdjustforConfoundersForalldataandendpoints,datacanbenormalizedtothebaselinecollectedvalues,andchangeinvalueatdifferenttimepointscanbecomparedusingthestatisticaltestsdescribedabove.
Inaddition,thereisaquestionincludedintheweeklysurveysassessinghowparticipantsaregenerallyfeelingabouttheirlife,whichtheyrespondtousingaratingscalefrom1(pessimistic)to9(optimistic).Ifnecessary,wecannormalizetheweeklysurveydatausingthisratingtoconfirmthatparticipantlifeandstressoutsidethestudyarenotaffectinghowtheyrespondtothesurveys.
QCPlansAllanalyseswillbeperformedby[CONTACT_433096].AllcodeusedfortheanalysiswillbesavedusingversioncontrolsoftwaresuchasGitintheformatorPythonnotebooks.Thesenotebookswillbereviewedby[CONTACT_433097],presentations,orpublicationsontheresultsofthestudy.
ProgrammingPlansAllcodefortheseanalyseswillbewrittenusingPython3inJupyternotebooks.Thepandaslibrarywillbeusedforimportingthedata,manipulatingitinadataframe,andexportingitasexcelorcomma-separatedfiles.TheNumpyandScipylibrarieswillbeusedforallstatisticalanalysisandtheSci-KitLearnlibrarywillbeusedformachinelearninganalyses.MatplotlibandSeabornlibrarieswillbeusedforvisualizationofthedataasgraphsandcharts.
InvestigatorConflictofInterest
Investigatorswilldiscloseanyconflictofinterest.
Anyinvestigatorwhohasaconflictofinterestwiththisstudy(patentownership,royalties,orfinancialgaingreaterthantheminimumallowableby[CONTACT_433098],etc.)musthavetheconflictreviewedby[CONTACT_433099]-sanctionedconflictmanagement
16
planthathasbeenreviewedandapprovedby[CONTACT_433100].Allinvestigatorswillfollowtheconflictofinterestpolicy.
R e f e r e n c e s
1.ScheimanJ,LuberJM,ChavkinTA,MacDonaldT,TungA,PhamL-D,etal.Meta’omicanalysisofeliteathletesidentifiesaperformance-enhancingmicrobethatfunctionsvialactatemetabolism.NatMed.2019;25:1104–9.
2.NgSK,HamiltonIR.Carbondioxidefixationby[CONTACT_433101]4anditsrelationtopropi[INVESTIGATOR_433080].CanJMicrobiol.1973;19:715–23.
3.GrossK,SantiagoM,KriegerJM,HageleAM,ZielinskaK,ScheimanJ,etal.AcuteImpactofVeillonellaatypi[INVESTIGATOR_433074]0054SupplementationonExercisePerformanceandLactateChanges:ARandomized,CrossoverPi[INVESTIGATOR_2268].Nutrients.InReview.
4.PreeceKE,GlávitsR,MurbachTS,EndresJR,HirkaG,VértesiA,etal.SafetyevaluationofVeillonellaatypi[INVESTIGATOR_433074]0054withgenotoxicityandsubchronictoxicologicalstudies.JApplToxicolJAT.2023;43:808–27.
17